Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary) ; MF 59
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Novartis Vaccines

    • Most Recent Events

    • 24 Nov 2015 According to FDA media release, Fluad was approved by U.S. FDA using the accelerated approval regulatory pathway for the prevention of seasonal influenza in people of 65 years of age and older.
    • 15 Sep 2015 Results were published in a CSL media release.
    • 15 Sep 2015 According to a CSL media release, based on results of this study the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US FDA has voted to recommend licensure of influenza vaccine FLUAD to help protect against seasonal influenza in those aged 65 years and older via accelerated approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top